Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.57 |
| ▸ | CDK8 | P49336 | 5/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | FES | P07332 | 2/20 | 0.48 |
| ▸ | ROS1 | P08922 | 2/20 | 0.48 |
| ▸ | FER | P16591 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.48 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18918861 | 0.83 | ULK1 (0.51) | ULK1CDK8KITMAP4K4CHEK2 | |
| SCHEMBL30469325 | 0.79 | ULK1 (0.67) | ULK1CDK8KITAXLNEK1 | |
| SCHEMBL17336876 | 0.78 | HDAC8 (0.64) | — | |
| SCHEMBL31447630 | 0.77 | ULK1 (0.71) | ULK1KITAXL | |
| SCHEMBL30469323 | 0.76 | KIT (0.72) | ULK1CDK8KITCHEK2CDK1 | |
| SCHEMBL15824749 | 0.76 | KIT (0.65) | KITMAP4K4CDK1FLT4IRAK1 | |
| SCHEMBL1778117 | 0.76 | HDAC6 (0.53) | ULK1CDK8KITCDK1AXL | |
| SCHEMBL18918718 | 0.76 | PLK4 (0.53) | ULK1CDK8MAP4K4ROS1FLT4 | |
| SCHEMBL18932419 | 0.75 | PLK4 (0.52) | ULK1MAP4K4ROS1FLT4KDR | |
| SCHEMBL18943990 | 0.74 | PLK4 (0.54) | ULK1MAP4K4ROS1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | claimed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | claimed |
| EP-3386980-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ULK1 495/4885CDK8 54/4885KIT 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.